Pelvic Lymphadenectomy

PROCEDURE4 trials

Sponsors

Kansai Medical University, NRG Oncology, Mayo Clinic, University of Washington

Conditions

Cervical cancerMuscle Invasive Bladder CarcinomaProstate AdenocarcinomaStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IIC Prostate Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IV Bladder Cancer AJCC v8

Phase 1

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Not yet recruitingNCT07579195

University of WashingtonMuscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8

Start: 2026-06-01End: 2029-12-31Target: 12Updated: 2026-05-14

Phase 2

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

RecruitingNCT07025369

Mayo ClinicProstate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 +1

Start: 2025-08-25End: 2026-12-31Target: 30Updated: 2026-03-13

Phase 3

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

RecruitingNCT05646316

NRG OncologyStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Start: 2022-12-07End: 2026-10-31Target: 428Updated: 2026-03-27

Unknown Phase

Laparoscopic radical hysterectomy

Active, not recruitingJPRN-UMIN000016501

Kansai Medical UniversityCervical cancer

Start: 2015-02-10Target: 3Updated: 2025-07-18